Tin tức & Cập nhật

Ebbs and flows in weight influence CVD risk in T2D patients
Ebbs and flows in weight influence CVD risk in T2D patients
31 Mar 2022 bởiAudrey Abella

In individuals with type 2 diabetes (T2D), greater variability in adiposity indices (BMI and waist circumference [WC]) was tied to increased risk of cardiovascular disease (CVD) outcomes and death – but an intensive weight loss programme mitigated this risk, a study suggests.

Ebbs and flows in weight influence CVD risk in T2D patients
31 Mar 2022
Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
31 Mar 2022 bởiSarah Cheung

Low-dose aspirin reduces risks of some common gastrointestinal (GI) cancers, including colorectal cancer (CRC) and gastric cancer (GC), in Chinese without atherosclerotic cardiovascular disease (ASCVD), compared with paracetamol, the first population-wide study from the University of Hong Kong (HKU) has shown.

Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
31 Mar 2022
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
30 Mar 2022
SGLT2i better than DDP4i at preventing heart failure hospitalization, death in T2DM
SGLT2i better than DDP4i at preventing heart failure hospitalization, death in T2DM
29 Mar 2022
BP-lowering drugs reduce death in older hypertensive COVID-19 patients
BP-lowering drugs reduce death in older hypertensive COVID-19 patients
29 Mar 2022

Antecedent use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) among older COVID-19 patients with hypertension results in fewer all-cause deaths, whether in-hospital or shortly after discharge, compared with no antecedent use of renin-angiotensin system inhibitors (RASIs), a study has shown.

BP-lowering drugs reduce death in older hypertensive COVID-19 patients
29 Mar 2022
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022 bởiJairia Dela Cruz

Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.

Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022